Quality Systems Issues Take Center Stage In Integra, Hologic Warning Letters

The US FDA has published warning letters to device firms Integra and Hologic. Both letters recount quality systems issues, with Integra’s centering on sterility while Hologic’s addresses a delay in noting safety signals from the company’s recalled BioZorb markers.

Red envelopes around a red exclamation point, with the exclamation point seen through a magnifying glass.
(MMD Creative/Shutterstock)

Compliance issues at Integra and Hologic facilities have caught the US Food and Drug Administration’s attention, with the agency publishing lengthy warning letters to both companies on 14 January.

The 18 December Hologic letter discusses the FDA’s findings during a late-summer 2024 inspection of the company’s Marlborough, Mass., headquarters. The facility makes BioZorb markers, which are currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medtech Insight

More from Policy & Regulation

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.